Shareholder advisory firm ISS issued a report today urging its clients to vote against 10 of Mylan‘s (NSDQ:MYL) board members and executive pay packages, including chief executive Heather Bresch and chairman Robert Coury.
The recommendation comes after a group of influential investors, including the New York City and State pension funds, encouraged other shareholders to vote against 6 board members and Coury.
ISS echoed the pension funds’ concerns, writing that the board mismanaged the widespread criticism around Mylan’s pricey EpiPen allergy auto-injector. The company is now the subject of numerous investigations into whether or not it overcharged Medicaid for years by misclassifying its device as a generic.
Get the full story at our sister site, Drug Delivery Business News.
The post Firm urges shareholders to vote against Mylan board nominees appeared first on MassDevice.